CNSP - CNS Pharmaceuticals gets French regulatory nod for brain cancer study

CNS Pharmaceuticals (NASDAQ:CNSP) said on Wednesday that it received approval from National Agency for the Safety of Medicine and Health Products and the People Protection Ethics Committee SUD-EST III in France to conduct a study of Berubicin to treat recurrent glioblastoma multiforme (GBM), an aggressive type of brain cancer. The French approvals come a day after the company said it received a regulatory nod from Swiss authorities for the same study. The study will enroll ~243 patients with GBM after failure of standard first line therapy. The patients will be randomized in a 2:1 ratio to receive Berubicin or chemotherapy drug lomustine for the evaluation of overall survival, the main goal of the study. Shares of the company had gained +14.68% on April 5.

For further details see:

CNS Pharmaceuticals gets French regulatory nod for brain cancer study